-
Mashup Score: 0Chemo + immunotherapy may improve bladder preservation, interim data from phase II study show - The Cancer Letter - 4 day(s) ago
Interim analysis of a clinical trial led by Fox Chase Cancer Center researchers shows promise for the treatment of patients with muscle-invasive bladder cancer. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Late on Friday, Feb. 7, the Trump administration announced that indirect costs paid on grants to U.S. medical research institutions would—starting immediately—henceforth be capped at a shocking rate of 15%. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
SPECIAL REPORT: Trump administration caps indirect costs at 15%, inviting injunctions, congressional scrutiny. The move could gut academic cancer research. https://t.co/ta8FSrolN4
-
-
Mashup Score: 020 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect - The Cancer Letter - 5 day(s) ago
Two decades ago, the discovery of the EGFR mutation transformed lung cancer treatment. The finding led to dramatically improved survival rates and ushered in the era of precision medicine and molecular profiling for lung cancer. In a special episode of the new Cancer Letter Podcast, Suresh S. Ramalingam, a lung cancer expert, executive director of […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect on how #LungCancer treatment has changed. https://t.co/OB3QahkWUp
-
-
Mashup Score: 0FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma - The Cancer Letter - 5 day(s) ago
FDA approved Adcetris (brentuximab vedotin) in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet-
FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma. https://t.co/f4feQCGLHV
-
-
Mashup Score: 0
Indirect costs are a component of a grant award that recognizes expenses for a project that, for efficiency’s sake, are aggregated across projects and divided proportionally to projects rather than explicitly charged to each project. They are influenced by location and services provided. To access this subscriber-only content please log in or subscribe.If your institution […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
From the chairs of ECOG-ACRIN (@eaonc): A perspective on indirect costs. Guest editorial by Peter O’Dwyer and Mitchell Schnall. https://t.co/XaQ5P5ezoe
-
-
Mashup Score: 0Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study finds - The Cancer Letter - 5 day(s) ago
Pfizer Inc. announced positive results from the phase III TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, demonstrating a statistically significant and clinically meaningful improvement in overall survival compared to placebo plus Xtandi in patients with metastatic castration-resistant prostate cancer, with or […]
Source: cancerletter.comCategories: General Medicine News, Onc News and JournalsTweet-
Talzenna + Xtandi improve OS in metastatic castration-resistant prostate cancer, phase III study (@pfizer) finds. https://t.co/FO5mXFoQ2Q
-
-
Mashup Score: 0
Dear colleagues, This column is going to cover some triggering topics. Please be advised. As I’ve watched the brief but intense war on our sensibilities, morality, and sense of stability, I am increasingly concerned about the person-level effect these changes and decisions can create. What I learned in my year in federal government and public […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
Preparing to take care of each other in ways we never imagined. Guest editorial by former NCI director, @KimrynRathmell. https://t.co/rCiIfECUpS
-
-
Mashup Score: 0
Aleksandar Sekulic was named physician-in-chief at the Translational Genomics Research Institute, part of City of Hope. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all site licenses are enrolled in sponsored accounts.Login Subscribe
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
Aleksandar Sekulic named physician-in-chief at @TGenResearch. https://t.co/F46Jya1b0r https://t.co/17BSBx4Ly4
-
-
Mashup Score: 1
Is the Community Outreach and Engagement mandate the next item on the chopping block as the Trump administration makes its mark on science policy? What about health disparities research? “If we got rid of Outreach and Engagement, I think it would be almost like losing a major foundational aspect of a cancer center,” Robert A. […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
On a new podcast, @VCUMassey’s Winn and @cityofhope’s Carpten discuss the mission—and the future—of cancer centers. https://t.co/IxuMCVyFk4
-
-
Mashup Score: 6World Cancer Day 2025: A symbol of personal and collective uncertainty - The Cancer Letter - 9 day(s) ago
My entire life I was told to respectfully question anything and everything, because questions equal answers, which provide understanding and thereby comfort—even with the uncomfortable. It’s simply in my DNA. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored […]
Source: cancerletter.comCategories: General Medicine News, Oncologists1Tweet-
#WorldCancerDay 2025: A symbol of personal and collective uncertainty. Guest editorial by @rfeinw (@NCCN). https://t.co/lPtFprUAMz
-
Chemo + immunotherapy may improve bladder preservation, interim data from phase II study (@FoxChaseCancer) show. https://t.co/lncvQk0Jzl